secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001193125-25-005649
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma furnishes January 2025 corporate presentation; no material new disclosures
--------------------------------------------------------------------------------

- Presentation reiterates UGN-102 PDUFA target date of June 13, 2025 and planned ODAC meeting.
- Highlights ongoing Phase 3 UTOPIA study for UGN-103 and planned Phase 3 for UGN-104.
- No new financial data or material changes disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/0001193125-25-005649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/d903812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer